Article

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.

Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Gastroenterology (Impact Factor: 12.82). 11/2007; 133(5):1414-22. DOI: 10.1053/j.gastro.2007.08.035
Source: PubMed

ABSTRACT To evaluate the safety and biological activity of visilizumab (a humanized anti-CD3 monoclonal antibody) and to determine a maximum tolerated dose in patients with severe ulcerative colitis that had not responded to 5 days of treatment with intravenous corticosteroids.
In this open-label phase 1 study, 32 subjects received visilizumab at a dose of 10 or 15 microg/kg, administered intravenously on 2 consecutive days. Clinical response was defined as a Modified Truelove and Witts Severity Index <10 with a minimum decrease of 3 points; remission was <4 points. Endoscopic remission was a Mayo endoscopic subscore of 0 or 1.
Eight patients received 15 microg/kg visilizumab. Because of dose-limiting toxicities (T-cell recovery >30 days in 2 of 8 patients), the dose was reduced to 10 microg/kg in 24 patients. On day 30, 84% of patients demonstrated a clinical response, 41% achieved clinical remission, and 44% achieved endoscopic remission. Forty-five percent of patients did not require salvage therapies or colectomy during the first year postdose. Mild to moderate symptoms of cytokine release occurred in 100% and 83% of patients in the 15- and 10-microg/kg dose groups, respectively. All patients exhibited a rapid decrease in circulating CD4(+) T-cell counts, which returned to baseline values by day 30 in 26 of 30 evaluable patients (86%). There were no serious infections.
Visilizumab had an acceptable safety profile at the 10-microg/kg dose level and may be clinically beneficial in patients with severe intravenous corticosteroid-refractory ulcerative colitis.

1 Bookmark
 · 
99 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: & Aims: T cells mediate the development of inflammation in inflammatory bowel disease (IBD). We investigated the effects of an antibody against CD3 called otelixizumab, which induces immune tolerance, in intestinal mucosa samples from patients. Intestinal tissues were isolated from individuals undergoing routine endoscopy or from patients undergoing intestinal surgery for colon cancer or IBD; healthy surrounding tissues were collected as controls. Isolated lamina propria mononuclear cells (LPMC) and mucosal tissue explants were incubated with otelixizumab for 24 or 48 hours. Production of inflammatory cytokines was determined by ELISA. Levels of 36 cytokines and chemokines and phosphorylation of 39 receptor tyrosine kinases and signaling molecules were measured using protein arrays. Immunoblot analysis was used to analyze T-cell transcription factors. Incubation of intestinal tissues or LPMC with otelixizumab reduced production of interferon γ, interleukin (IL)17A, and other inflammatory cytokines and chemokines, simultaneously increasing production of IL10. Mucosal biopsies from patients with IBD retained inflammation-associated tyrosine phospho-protein profiles ex vivo. Incubation of the inflamed tissue with otelixizumab reduced phosphorylation of these proteins to levels observed in control tissues. Otelixizumab also markedly reduced phosphorylation of proteins associated with T-cell receptor activation. Neutralization of IL10 blocked the anti-inflammatory effects of otelixizumab. We observed anti-inflammatory effects of anti-CD3 in inflamed intestinal tissues from patients with IBD. The antibody appears to downregulate T-cell activation via IL10.
    Gastroenterology 04/2014; · 12.82 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Die Colitis ulcerosa (CU) ist eine komplexe Erkrankung, bei der die Interaktion von genetischen, umweltbedingten und mikrobiellen Faktoren ein Fortschreiten der chronischen Darmentzündung bedingt, die schließlich zu einer ausgeprägten Gewebefibrosierung führt. Diskussion Die vorliegende Übersichtsarbeit beschreibt den aktuellen Stand der Fachliteratur zur CU bezüglich einer genetischen Prädisposition und der pathophysiologischen Rolle involvierter Zytokine (z. B. IL-13, IL-23, TGF-β1), insbesondere hinsichtlich des IL-12/IL-23-Weges im Krankheitsprozess. Auch auf den beteiligten Immunzellen (z. B. T-Zellen, Epithelzellen, Fibroblasten) liegt ein besonderer Fokus. Zudem gibt sie einen Überblick über die aktuellen Therapieansätze bei dieser Erkrankung. Diese Therapie-Ansätze zielen selektiv auf eine Blockade der Aktivierung der beteiligten Zelltypen, auf eine Inhibierung der Migration von Immunzellen zum Ort der Entzündung sowie auf Anti-Zytokin-Strategien. Diese könnten – bei rechtzeitigem Einsatz – die Aufrechterhaltung der Entzündungsmechanismen verhindern und so eine Fibrose vermeiden. Tiermodelle, welche wesentliche Befunde zum Verständnis chronisch-entzündlicher Darmerkrankungen beim Menschen geliefert haben, werden in ihrem diesbezüglichen Kontext kurz diskutiert.
    coloproctology 34(6).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Significant advances have been made during the past decade in the understanding of autoimmune diseases and in the development of therapeutics targeting various immune pathways. T-cell-mediated immune dysregulation occurs in a variety of autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Inhibition of the T-cell function using CTLA-4Ig is currently approved for management of rheumatoid arthritis. Select therapies targeting adhesion molecules are used for the management of patients with psoriasis and multiple sclerosis. Therapeutics targeting tumor necrosis factor-α (TNF-α), a cytokine secreted by T cells, is widely used in patients with rheumatoid arthritis and inflammatory bowel disease. Furthermore, several therapies target a variety of molecules related to T cells that are under development or undergoing clinical trials. Drug Dev Res 72:585–597, 2011. © 2011 Wiley Periodicals, Inc.
    Drug Development Research 11/2011; 72(7). · 0.87 Impact Factor